Payment overview · 2025
General Payments
$355.62
16 reported records · 5 companies
Healthcare provider profile · identity verified
Christopher B Paronish, MD
Allopathic & Osteopathic Physicians|Family Medicine · CARROLLTOWN, PA · NPI 1053332601
Verified facts
What the public records show
CMS Open Payments records show Christopher B Paronish, MD received $355.62 in general payments during 2025 across 16 reported records.
Ardelyx, Inc. accounted for 68.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 373 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $243.16 | 68.4% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.36 | 16.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.93 | 5.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.38 | 5.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.79 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $355.62 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $243.16 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.36 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.66 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 168 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
32 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
168 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
373 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 529 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 456 | 104 |
| Ozempic | Semaglutide | 373 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 362 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 80 |
| Lorazepam | Lorazepam | 314 | 52 |
| Methylprednisolone | Methylprednisolone | 267 | 187 |
| Potassium Chloride | Potassium Chloride | 225 | 51 |
| Furosemide | Furosemide | 221 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 216 | 49 |
| Losartan Potassium | Losartan Potassium | 197 | 51 |
| Carvedilol | Carvedilol | 190 | 41 |
| Azithromycin | Azithromycin | 189 | 150 |
| Omeprazole | Omeprazole | 187 | 39 |
| Lisinopril | Lisinopril | 185 | 49 |
| Jardiance | Empagliflozin | 168 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 34 |
| Sertraline Hcl | Sertraline Hcl | 157 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 34 |
| Metformin Hcl Er | Metformin Hcl | 146 | 35 |
| Irbesartan | Irbesartan | 143 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 28 |
| Gabapentin | Gabapentin | 139 | 30 |
| Simvastatin | Simvastatin | 139 | 31 |
| Ezetimibe | Ezetimibe | 137 | 24 |
| Synthroid | Levothyroxine Sodium | 127 | 24 |
| Eliquis | Apixaban | 126 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 26 |
| Repatha Sureclick | Evolocumab | 96 | suppressed |
| Atenolol | Atenolol | 95 | 19 |
| Allopurinol | Allopurinol | 92 | 23 |
| Alprazolam | Alprazolam | 86 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 86 | 16 |
| Metformin Hcl | Metformin Hcl | 86 | 20 |
| Montelukast Sodium | Montelukast Sodium | 83 | 16 |
| Benazepril Hcl | Benazepril Hcl | 81 | 14 |
| Tradjenta | Linagliptin | 80 | 11 |
| Famotidine | Famotidine | 78 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 15 |
| Temazepam | Temazepam | 68 | 11 |
| Xarelto | Rivaroxaban | 68 | 12 |
| Vascepa | Icosapent Ethyl | 64 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 16 |
| Celecoxib | Celecoxib | 60 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 14 |
| Glimepiride | Glimepiride | 59 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 34 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 56 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 54 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | suppressed |
| Valsartan | Valsartan | 48 | 12 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Finasteride | Finasteride | 45 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 42 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 26 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Prolia | Denosumab | 32 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Trulance | Plecanatide | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 12 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Livalo | Pitavastatin Calcium | 19 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Crestor | Rosuvastatin Calcium | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Matzim La | Diltiazem Hcl | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.62 · 16 records | Ardelyx, Inc. | IBSRELA, JARDIANCE, OTEZLA, REPATHA, REXULTI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error